Background/Aims:Risks of hepatocellular carcinoma(HCC) following hepatitis B and/or hepatitis C virus(HBV/HCV) infection are well known,those for other cancers are less well understood.The aim was to quantify the risk...Background/Aims:Risks of hepatocellular carcinoma(HCC) following hepatitis B and/or hepatitis C virus(HBV/HCV) infection are well known,those for other cancers are less well understood.The aim was to quantify the risk of cancers among persons diagnosed with HBV/HCV infections.Methods:The data from a cohort of 39109 HBV,75834 HCV,and 2604 HBV/HCV co-infected persons notified to the State health department,1990-2002,were probabilistically linked to the Cancer Registry and standardised incidence ratios(SIRs) for cancer were calculated.Results:The match rate for any cancer was 2.7%,2.3% and 3.3% for HBV,HCV and HBV/HCV co-infected notifications.SIRs for HCC were 30.6(95% CI 25.7-36.5) ,22.7(95% CI 19.1-26.5) and 30.3(95% CI 13.6-67.5) ,respectively.Increased risk was detected for Burkitt’s lymphoma and HBV(SIR 12.9,95% CI 5.4-30.9) and immunoproliferative malignancies following HCV(SIR 5.6,95% CI 1.8-17.5) .Conclusions:The risk of HCC in the infected cohort was 20-30 times greater than in the uninfected population with SIRs two to three times greater than those for the other HBV/HCV infection associated cancers.The modest though significant risk of immunoproliferative malignancies associated with HCV infection is consistent with recent findings.展开更多
文摘Background/Aims:Risks of hepatocellular carcinoma(HCC) following hepatitis B and/or hepatitis C virus(HBV/HCV) infection are well known,those for other cancers are less well understood.The aim was to quantify the risk of cancers among persons diagnosed with HBV/HCV infections.Methods:The data from a cohort of 39109 HBV,75834 HCV,and 2604 HBV/HCV co-infected persons notified to the State health department,1990-2002,were probabilistically linked to the Cancer Registry and standardised incidence ratios(SIRs) for cancer were calculated.Results:The match rate for any cancer was 2.7%,2.3% and 3.3% for HBV,HCV and HBV/HCV co-infected notifications.SIRs for HCC were 30.6(95% CI 25.7-36.5) ,22.7(95% CI 19.1-26.5) and 30.3(95% CI 13.6-67.5) ,respectively.Increased risk was detected for Burkitt’s lymphoma and HBV(SIR 12.9,95% CI 5.4-30.9) and immunoproliferative malignancies following HCV(SIR 5.6,95% CI 1.8-17.5) .Conclusions:The risk of HCC in the infected cohort was 20-30 times greater than in the uninfected population with SIRs two to three times greater than those for the other HBV/HCV infection associated cancers.The modest though significant risk of immunoproliferative malignancies associated with HCV infection is consistent with recent findings.
